UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 25,130 Shares of CureVac (NASDAQ:CVAC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in shares of CureVac (NASDAQ:CVAC) by 8.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 277,166 shares of the company’s stock after selling 25,130 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.12% of CureVac worth $815,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Signaturefd LLC lifted its position in CureVac by 26.9% during the 3rd quarter. Signaturefd LLC now owns 27,970 shares of the company’s stock worth $82,000 after buying an additional 5,927 shares in the last quarter. Green Alpha Advisors LLC lifted its position in shares of CureVac by 41.3% during the third quarter. Green Alpha Advisors LLC now owns 27,319 shares of the company’s stock worth $80,000 after purchasing an additional 7,979 shares in the last quarter. Ballentine Partners LLC grew its stake in shares of CureVac by 58.6% during the third quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock valued at $67,000 after purchasing an additional 8,406 shares during the last quarter. Private Advisor Group LLC bought a new stake in shares of CureVac during the third quarter valued at approximately $30,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of CureVac in the third quarter valued at approximately $35,000. Institutional investors own 17.26% of the company’s stock.

CureVac Stock Performance

Shares of NASDAQ:CVAC opened at $2.99 on Friday. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. CureVac has a 1-year low of $2.21 and a 1-year high of $5.28. The stock has a market capitalization of $669.40 million, a P/E ratio of 5.44, a P/E/G ratio of 0.24 and a beta of 2.59. The business has a 50-day moving average price of $2.84 and a two-hundred day moving average price of $3.19.

Analysts Set New Price Targets

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a report on Monday, September 16th.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.